Navigation Links
Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
Date:10/25/2007

217,665 200,497

Accumulated other comprehensive income - 3

Deficit accumulated during the

development stage (191,141) (155,894)

Total stockholders' equity 26,558 44,635

Total liabilities and stockholders' equity $60,044 $72,289

FAVRILLE, INC.

(a development stage company)

STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

Unaudited

Three Months ended Nine Months ended

September 30, September 30,

2007 2006 2007 2006

Operating expenses:

Research and

development $9,480 $7,487 $27,100 $23,370

General and

administrative 2,938 2,605 8,798 8,226

Total operating

expenses 12,418 10,092 35,898 31,596

Interest income 361 773 1,423 2,004

Interest expense (271) (266) (772) (644)

Other expense - - - (29)

Total other income, net 90 507 651 1,331

Net loss applicable to

common stockholders $(12,328) $(9,585) $(35,247) $(30,265)

Historical net loss

per share:

Basic and diluted $(0.37) $(0.33) $(1.10) $(1.13)

Weighted-average

shares - basic and

diluted 32,928,733 28,805,214 32,038,726 26,679,507

FAVRILLE, INC.

(a development stage company)


'/>"/>

SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
2. Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
5. XTL Provides Update on Phase I Clinical Trial of XTL-2125
6. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
7. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
8. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
9. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
10. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
11. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... and Markets ( http://www.researchandmarkets.com/research/5hkm2f/medical_oxygen ) has announced ... Global Strategic Business Report" report to their offering. ... Medical Oxygen Systems in US$ Thousands by the following ... Regulators, and Oxygen Conserving Devices. The report provides separate ... , Japan , Europe ...
(Date:4/17/2015)... DULLES, Va. , April 17, 2015 ... and distribution of radiopharmaceuticals, announced today that it has ... IBA Molecular North America, Inc. (IBAM NA), to Illinois Health ... continue to operate as an independent company headquartered in ... well positioned to take advantage of new product and ...
(Date:4/17/2015)... TWi Pharmaceuticals, Inc. ("TWi", Stock Ticker:4180.TT) today ... USA , has obtained state sales licenses from ... been in close contact with the major nationwide retail ... own label specialty generic products sold through these nationwide ... According to IMS Health, the U.S. pharma ...
Breaking Medicine Technology:Medical Oxygen Systems - 2015 Global Strategic Business Report Featuring Leading Players, Caire, Invacare & Philips Respironics 2Health Care System to Acquire IBA Molecular North America 2Health Care System to Acquire IBA Molecular North America 3
... of Bavituximab in ... Carboplatin and Paclitaxel-, TUSTIN, Calif., Jan. 22 ... biopharmaceutical,company developing monoclonal antibodies for the treatment of cancer ... Phase II,clinical protocol to study bavituximab in combination with ...
... II Investigational Trial Published in CANCER: the Journal of the ... ... Cell Therapeutics, Inc.,(CTI) (Nasdaq: CTIC ; MTAX) announced ... the journal CANCER demonstrate that the,addition of radioimmunotherapy (RIT) to ...
Cached Medicine Technology:Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 2Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 3Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 4Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent 2Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent 3Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent 4Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent 5
(Date:4/18/2015)... April 18, 2015 On April 14th, 2015, ... Report , which they say, “exposes a tactical shift by ... malware variants were introduced in 2014 - almost a million ... Day threats to be identified and patched by prominent manufacturers ... clear that doing business in a digital world can be ...
(Date:4/18/2015)... 18, 2015 “ ArcAngel ” was featured ... a look at the latest and coolest applications ... the host of AppWatch and technology expert, conducted the app ... safety app. , In a turbulent world, people may ... 911 should always be their first move, but some situations ...
(Date:4/18/2015)... French physician and gastronome Anthelme Brillat-Savarin understood the ... “Tell me what you eat, and I will tell ... stress or sadness has often been attributed to women, ... collected from their Emotional Eating Test reveals ... for different reasons. , Collecting data from 521 emotional ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 John Evans, ... Party on the Patio from 2 p.m. to 3 ... located at 1320 Executive Ct. in Pekin, Illinois, serves ... who need some help to maintain their independence. , ... and tropical treats will be served during the luau. ...
(Date:4/17/2015)... April 17, 2015 ERGO-Pedic Products, LLC, ... introducing two new products to help a broader range ... pain relief are the second most common visitors to ... product, designed specifically to help relieve sitting pain. Then, ... and thousands of happy customers later, we began getting ...
Breaking Medicine News(10 mins):Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5Health News:A Personal Safety Application was Featured on NewsWatch Television 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 3Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 4Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 6Health News:John Evans Supportive Living Community Prepares for Party on the Patio 2Health News:Seat Cushion Company Credits Customer Driven Design For Two New Products 2
... with 21 pens of cattle in commercial feedlots ... Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian ... a large-scale commercial beef feedlot study with the ... have been published in this month,s issue of ...
... Tens of Thousands of Americans Die Unnecessarily Every Year From Preventable ... ... 13, 2009 -- In support of National Patient Safety Awareness ... and compliance solutions for the healthcare industry, has produced an educational ...
... Cirangle, the most experienced bariatric surgeon in the state of Hawaii is ... the outer islands, Dr. Cirangle,s weight loss surgery patients will now have ... ... (PRWEB) March 13, 2009 -- As America,s fight with obesity continues, it ...
... Center for Refugee Health and Human Rights (BCRHHR) ... the large number of Tibetan refugee monks who ... Boston suffering from symptoms of traumatic stress, interfering ... by their traditional healers as having srog-rLung, a ...
... severely limit the movement of your pet, especially in the winter. ... industry in supplying the best medications to treat arthritis and joint pain ... ... leading online veterinary pharmacy and supplier of pet meds , announced ...
... National Association of Boards of Pharmacy(R) (NABP(R)) is one ... of Excellence in the first round of the 2009 ... sponsored by the American Society of Association Executives (ASAE) ... in Mount Prospect, IL, received the award for its ...
Cached Medicine News:Health News:Econiche(TM) Vaccine Shows 92% Reduction in Colonization of E. coli O157 in Vaccinated Cattle 2Health News:Econiche(TM) Vaccine Shows 92% Reduction in Colonization of E. coli O157 in Vaccinated Cattle 3Health News:Econiche(TM) Vaccine Shows 92% Reduction in Colonization of E. coli O157 in Vaccinated Cattle 4Health News:Econiche(TM) Vaccine Shows 92% Reduction in Colonization of E. coli O157 in Vaccinated Cattle 5Health News:Econiche(TM) Vaccine Shows 92% Reduction in Colonization of E. coli O157 in Vaccinated Cattle 6Health News:Quantros Produces Video Detailing Enormous Problem of Preventable Medical Errors Plaguing The U.S. Healthcare System 2Health News:Quantros Produces Video Detailing Enormous Problem of Preventable Medical Errors Plaguing The U.S. Healthcare System 3Health News:Hawaii's Most Experienced and Only Fellowship-Trained Weight Loss Surgeon Now Coming to Hilo 2Health News:Hawaii's Most Experienced and Only Fellowship-Trained Weight Loss Surgeon Now Coming to Hilo 3Health News:Researchers discover ways of integrating treatment of traumatized Tibetan refugee monks 2Health News:Researchers discover ways of integrating treatment of traumatized Tibetan refugee monks 3Health News:PetCareRx Reinforces its Range of Arthritis and Joint Care Products for Winter 2Health News:NABP Wins ASAE's 2009 Associations Advance America Award of Excellence 2Health News:NABP Wins ASAE's 2009 Associations Advance America Award of Excellence 3
... is a handheld, noninvasive ultrasound instrument that ... operate, so any staff member can scan ... images from exams and print BVI 6100 ... just log on to ScanPoint®, Diagnostic Ultrasound's ...
... The Mobile BladderScan® BVI 6400 calculates ... ultrasound technology. V-MODE® ultrasound is accurate, ... seconds, the BladderScan® measures ultrasonic reflections ... planes, creates a 3-dimensional image of ...
... EXP Injectable Bulking Agent is ... suspended in a water-based carrier ... Agent is indicated for the ... stress urinary incontinence due to ...
... The MIS is designed to ... in the area of the mid-urethra. ... 30 minutes, and can be performed ... department which allows the patient to ...
Medicine Products: